NIKKEI 225
37,780.35 +151.87 (+0.40%) HANG SENG
17,618.19 +333.65 (+1.93%) CRUDE OIL
83.83 +0.26 (+0.31%) GOLD FUTURES
2,345.00 +2.50 (+0.11%) DOW
38,085.80 -375.12 (-0.98%) Bitcoin GBP
51,536.75 +152.04 (+0.30%)
Voyager Therapeutics, Inc. (VYGR)
After hours:
Voyager Therapeutics, Inc.
75 Hayden Avenue
Lexington, MA 02421
United States
857 259 5340
https://www.voyagertherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 162
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Dr. Alfred W. Sandrock Jr., M.D., Ph.D. | President, CEO & Director | 825.41k | N/A | 1958 |
| Dr. Krystof Bankiewicz M.D., Ph.D. | Founder | N/A | N/A | N/A |
| Dr. Guangping Gao Ph.D. | Founder & Member of Scientific Advisory Board | N/A | N/A | N/A |
| Dr. Mark A. Kay M.D., Ph.D. | Founder | N/A | N/A | 1959 |
| Dr. Phillip D. Zamore Ph.D. | Founder & Member of Scientific Advisory Board | N/A | N/A | N/A |
| Ms. Robin Swartz | COO, Principal Financial & Accounting Officer and Acting Chief Business Officer | N/A | N/A | 1971 |
| Mr. Todd Carter Ph.D. | Chief Scientific Officer | N/A | N/A | 1970 |
| Ms. Jacquelyn Fahey Sandell Esq., J.D. | Chief Legal Officer | N/A | N/A | N/A |
| Ms. Michelle Quinn Smith | Chief Human Resources Officer | N/A | N/A | N/A |
| Mr. G. Andre Turenne | Advisor | 600.3k | N/A | 1974 |
Description
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Corporate governance
Voyager Therapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 3; Board: 6; Shareholder rights: 8; Compensation: 8.
